Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

• 資料種別: 記事
• タイトル: Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105
• 著者標目: Nobuyuki Yamamoto; Kazuhiko Nakagawa; https://orcid.org/0000-0003-1284-9776; Yasumasa Nishimura; Kayoko Tsujino; https://orcid.org/0000-0002-8679-298X; Miyako Satouchi; Shinzoh Kudo; Toyoaki Hida; Masaaki Kawahara; Koji Takeda; Nobuyuki Katakami; Toshiyuki Sawa; https://orcid.org/0000-0003-0705-3781; Soichiro Yokota; Takashi Seto; Fumio Imamura; Hideo Saka; Yasuo Iwamoto; Hiroshi Semba; Yasutaka Chiba; Hisao Uejima; Masahiro Fukuoka
• 出版年月日等: 2010-08-10
• 出版年（W3CDTF）: 2010-08-10
• タイトル（掲載誌）: Journal of Clinical Oncology
• 巻号年月日等（掲載誌）: 28 23
• 掲載巻: 28
• 掲載号: 23
• 掲載ページ: 3739-3745
• 掲載年月日（W3CDTF）: 2010-08-10
• ISSN（掲載誌）: 0732183X
• 出版事項（掲載誌）: American Society of Clinical Oncology (ASCO)
• 件名標目: Adult; Male; Lung Neoplasms; Paclitaxel; Vindesine; Mitomycin; Middle Aged; Irinotecan; Combined Modality Therapy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Antineoplastic Combined Chemotherapy Protocols; Humans; Camptothecin; Female; Radiotherapy, Adjuvant; Cisplatin; Aged
• 対象利用者: 一般
• 標準番号（その他）: PMID : 21402605
• DOI: 10.1200/jco.2009.24.5050
• 作成日（W3CDTF）: 2010-07-13
• 関連情報（URI）: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.24.5050
• 参照: Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer; https://cir.nii.ac.jp/crid/1050001202675032704; Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters; https://cir.nii.ac.jp/crid/1050003824925953920; A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients; https://cir.nii.ac.jp/crid/1050008089757611520; Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L); https://cir.nii.ac.jp/crid/1050575520345072384; Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study; https://cir.nii.ac.jp/crid/1050852814735475968; Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy; https://cir.nii.ac.jp/crid/1360004236848191488; Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients; https://cir.nii.ac.jp/crid/1360004239691287808; Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer; https://cir.nii.ac.jp/crid/1360009142580686080; Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer; https://cir.nii.ac.jp/crid/1360013168861509376; Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study); https://cir.nii.ac.jp/crid/1360017282431971584; Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401; https://cir.nii.ac.jp/crid/1360285706178133888; Keys to successful induction chemoradiotherapy followed by surgery for stage III/N2 non-small cell lung cancer; https://cir.nii.ac.jp/crid/1360285706244426112; Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer; https://cir.nii.ac.jp/crid/1360285706966328320; Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non–small cell lung cancer; https://cir.nii.ac.jp/crid/1360285709616065152; Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer; https://cir.nii.ac.jp/crid/1360294643826039168; A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis; https://cir.nii.ac.jp/crid/1360298754813444992; Novel <scp>NRF2</scp>‐activated cancer treatments utilizing synthetic lethality; https://cir.nii.ac.jp/crid/1360298757161837440; Changing Treatment Paradigms of Radiotherapy for the Treatment of Lung Cancer; https://cir.nii.ac.jp/crid/1360298757208343168; Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study); https://cir.nii.ac.jp/crid/1360302865539190272; Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460; https://cir.nii.ac.jp/crid/1360565167540167680; Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer; https://cir.nii.ac.jp/crid/1360565170746028032; A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer; https://cir.nii.ac.jp/crid/1360567181300266496; A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L); https://cir.nii.ac.jp/crid/1360567182018252800; The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells; https://cir.nii.ac.jp/crid/1360567183482822784; Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia; https://cir.nii.ac.jp/crid/1360568467211526784; A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non–small-cell Lung Cancer; https://cir.nii.ac.jp/crid/1360572092562113152; Surgery for NSCLC in the era of personalized medicine; https://cir.nii.ac.jp/crid/1360846641743763840; Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer; https://cir.nii.ac.jp/crid/1360848656131843712; Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601; https://cir.nii.ac.jp/crid/1360848657280992896; Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities; https://cir.nii.ac.jp/crid/1360848659560666752; Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled Analysis of the Literature; https://cir.nii.ac.jp/crid/1360848659826019968; Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study; https://cir.nii.ac.jp/crid/1360849944495316224; Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer; https://cir.nii.ac.jp/crid/1363104598396720512; 肺癌化学放射線療法に伴う放射線食道炎に対するポラプレジンクの後方視的検討; https://cir.nii.ac.jp/crid/1390001204681542016; N2非小細胞肺癌の治療方針と今後の臨床研究の展望; https://cir.nii.ac.jp/crid/1390001204682538752; 三次元治療計画と線量分割法; https://cir.nii.ac.jp/crid/1390001204683805952; 局所進行肺癌に対する集学的治療とその問題点; https://cir.nii.ac.jp/crid/1390001288123014400; Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer; https://cir.nii.ac.jp/crid/1390282679221787264; N2切除可能非小細胞肺癌に対する化学放射線療法の可能性（WJOG5008Lより）; https://cir.nii.ac.jp/crid/1390282679660501888; 臨床病期III期肺非小細胞癌に対する治療戦略; https://cir.nii.ac.jp/crid/1390282679852474880; 局所進行肺癌で放射線療法・化学療法を中心とした検討; https://cir.nii.ac.jp/crid/1390282679990290560; 2．肺癌：放射線治療; https://cir.nii.ac.jp/crid/1390282681423266176; 放射線治療のupdate; https://cir.nii.ac.jp/crid/1390282763073602560; 化学放射線治療にて長期生存を得た原発不明縦隔リンパ節癌の4例; https://cir.nii.ac.jp/crid/1390287860631882496; 化学放射線療法後デュルバルマブの投与回避要因（TOPGAN2020-01）; https://cir.nii.ac.jp/crid/1390568456340306304; III期非小細胞肺癌に対する化学放射線療法の変遷と新しい時代; https://cir.nii.ac.jp/crid/1390845713066336384; 日本肺癌学会による臨床試験統合データベースの構築と新規研究実施のためのデータ共有; https://cir.nii.ac.jp/crid/1390859547229982208
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Crossref; https://www.crossref.org

• 要約等: <jats:sec><jats:title>Purpose</jats:title><jats:p> This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-gener...